Kuros Biosciences raises €37.0M Growth round
21 March 2012· Schlieren, Switzerland· health, orthobiologics, biotech, materials, b2b, deep_hardware
The funding was to recapitalize Cytos, advance its programs, specifically conduct a global multi-center Phase IIb clinical trial with its lead product CYT003-QbG10 in patients suffering from allergic asthma, and develop additional pipeline programs.
Investors
LeadvenBio
Also participating
AmgenAbingworthAisling Capital
About Kuros Biosciences
Stage
Growth
Headquarters
Schlieren, Switzerland
Founded
2000
Team Size
51–200
Sectors
healthorthobiologicsbiotechmaterialsb2bdeep_hardware